SCM
RCUS icon

Sterling Capital Management’s Arcus Biosciences RCUS Stock Holding History

Sterling Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.5K Sell
634
-501
-44% -$12.4K ﹤0.01% 1897
2026
Q1 		$24.5K Sell
1,135
-440
-28% -$9.5K ﹤0.01% 1934
2025
Q4 		$37.5K Buy
1,575
+196
+14% +$4K ﹤0.01% 1915
2025
Q3 		$18.8K Buy
1,379
+761
+123% +$7.91K ﹤0.01% 2175
2025
Q2 		$5.03K Buy
618
+562
+1,004% +$4.8K ﹤0.01% 2513
2025
Q1 		$440 Hold
56
– – ﹤0.01% 2980
2024
Q4 		$834 Hold
56
– – ﹤0.01% 2977
2024
Q3 		$856 Buy
+56
New +$883 ﹤0.01% 2616

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Sterling Capital Management's RCUS Position: Q2 2026 in Review

Sterling Capital Management reduced its Arcus Biosciences (RCUS) stake by 44% in Q2 2026, selling an estimated $12.4K and leaving 634 shares worth $19.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1897.

Sterling Capital Management first reported a position in RCUS in Q3 2024 and has held it in 8 quarters since. The position peaked at $37.5K in Q4 2025. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Sterling Capital Management held 634 shares of Arcus Biosciences worth $19.5K as of Q2 2026.
  • Sterling Capital Management sold 501 Arcus Biosciences shares in Q2 2026, an estimated $12.4K.
  • Arcus Biosciences made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1897 holding.
  • Sterling Capital Management first reported a position in Arcus Biosciences in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Arcus Biosciences position peaked at $37.5K in Q4 2025.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.